A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men

J Am Acad Dermatol. 2007 Nov;57(5):767-74. doi: 10.1016/j.jaad.2007.04.012. Epub 2007 Aug 29.

Abstract

Background: An alternative to currently marketed topical minoxidil solutions is desirable.

Objective: To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA).

Methods: This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5% MTF.

Results: At week 16 compared with baseline, there was a statistically significant increase in (1) hair counts in the 5% MTF group versus placebo (P < .0001) and (2) subjective assessment of improved hair loss condition (P < .0001) in the 5% MTF group versus placebo. The 5% MTF was well tolerated over a 52-week period.

Limitations: There was no collection of efficacy data beyond 16 weeks.

Conclusions: We believe that 5% MTF is a safe and effective treatment for men with AGA.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Alopecia / drug therapy*
  • Alopecia / pathology
  • Double-Blind Method
  • Hair / pathology
  • Humans
  • Male
  • Middle Aged
  • Minoxidil / administration & dosage*
  • Minoxidil / adverse effects
  • Minoxidil / therapeutic use
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome

Substances

  • Minoxidil